About US
Contact us
-
Europe makes Sanofi chief thankful for emerging marketsAlthough Sanofi ($SNY) CEO Christopher Viehbacher (photo)sees a glimmer of light at the end of the long Eurozone tunnel, he's still glad the French drugmaker doesn't depend on Europe as much as it u2012/1/29
-
Murdoch bows out of GSK board to focus on workNews Corp's James Murdoch has enough on his plate these days, what with moving to the U.S. and taking over as COO, not to mention answering pointed questions about that phone-hacking scandal. No tim2012/1/29
-
Foreign pharma deals snag on new Indian rulesPharma companies are seeing the fallout from new M&A rules adopted by the Indian government. Late last year,Indian officials introduced a new deal-review process that has replaced the automati2012/1/21
-
Pharma's earnings laggards are dividend starsAs we move into earnings season, Reuters has crunched the numbers on your favorite Big Pharma companies and put the results into a handy-dandy bar chart that ranks them by various measures: P/E rati2012/1/21
-
Merck to pay up to $37M in Canadian Vioxx caseMerck ($MRK) is wrapping up a Canadian class action suit by pledging to pay up to $37 million to Vioxx patients who developed heart problems after using the drug. The settlement includes $10 milli2012/1/20
-
Can AstraZeneca continue to swear off major M&A?Can AstraZeneca ($AZN) CEO David Brennan stick to his no-megadeals diet? Analysts are beginning to wonder, says Bloomberg, now that three of the company's promising drug candidates have stumbled. Th2012/1/20
-
Pharma gets its close-up in new Hollywood filmsPharma films are all the rage in Hollywood these days--and several more are on the horizon. After "Love and Other Drugs" turned Jake Gyllenhaal into a Viagra rep and "Contagion" made a vaccine res2012/1/19
-
UPDATED: J&J said to settle TX Risperdal case for $158MJohnson & Johnson ($JNJ) says it will pay $158 million to settle a high-profile Texas suit alleging that it defrauded the state by misleading doctors about its antipsychotic drug Risperdal. Bloo2012/1/19
-
Novartis hammers out deal to keep Nyon plant openDon't accuse Novartis ($NVS)CEO Joe Jimenez (photo) of refusing to listen. After workers in Nyon, Switzerland, stopped work to protest their plant's closure, the company sat down to talk about oth2012/1/18
-
Generics market to bulk up by $100B in 5 yearsWith leading generics makers moving into branded drugs as a hedge against slowing growth of the copycat industry, one might think the knockoff-drug business has transfigured into a tortoise, or pe2012/1/18